(NasdaqGM:KYMR), WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares of […]
(NasdaqGM:GPCR), SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the commencement of a proposed underwritten public offering, subject to market and other conditions, to issue and sell $500 million
(NYSE:KRG), INDIANAPOLIS, Dec. 08, 2025 (GLOBE NEWSWIRE) — Kite Realty Group (NYSE: KRG), a premier owner and operator of high-quality, open-air grocery-anchored centers and vibrant mixed-use assets, today announced that the Company closed on the disposition of a portfolio that includes eight large-format power and community centers for gross proceeds of $429.0 million. Large-Format Power
(NasdaqGM:WVE), CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today that it has commenced an underwritten public offering of $250 million in aggregate of its ordinary
(NasdaqGM:VERA), BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of shares
(NasdaqGM:FULC), CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.(R) (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. Fulcrum
Kymera Therapeutics Announces Proposed Public Offering GlobeNewswire December 08, 2025 WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $500.0 million of shares
Kite Realty Group Completes $474 Million in Dispositions and $86.1 Million of Additional Share Repurchases GlobeNewswire December 08, 2025 INDIANAPOLIS, Dec. 08, 2025 (GLOBE NEWSWIRE) — Kite Realty Group (NYSE: KRG), a premier owner and operator of high-quality, open-air grocery-anchored centers and vibrant mixed-use assets, today announced that the Company closed on the disposition of
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants GlobeNewswire December 08, 2025 CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”),
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants GlobeNewswire December 08, 2025 SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the commencement